Recently, a Tat peptide containing GluN2B C‐ter (NA‐1; Aarts et al, 2002) has provided the first strong evidence that neuroprotection is feasible in human ischemic stroke (Hill et al, 2012). The gene discussed is TAT; the disease is ischemic stroke.